At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.6B, above the global median of $1.14B
- FinancialsAltman Z-Score 0.72: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.60BUSDvs all stocks (USD)
Revenue (TTM)
169.90MUSDvs all stocks (USD)
Profit Margin
-88.19%vs Biotechnology peers
Beta
1.62xvs all stocks
52-Week Change
-13.50%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
1.60BUSDvs all stocks (USD)
Enterprise Value
1.34BUSDvs all stocks (USD)
Forward P/E
-300.67xvs Biotechnology peers
Price to Sales (TTM)
9.32xvs Biotechnology peers
Price to Book (MRQ)
6.21xvs Biotechnology peers
Enterprise to Revenue
7.88xvs Biotechnology peers
Enterprise to EBITDA
-9.88xvs Biotechnology peers
Gross Margin
70.11%vs Biotechnology peers
Profit Margin
-88.19%vs Biotechnology peers
Operating Margin
-161.06%vs Biotechnology peers
Return on Assets (TTM)
-12.36%vs Biotechnology peers
Return on Equity (TTM)
-47.81%vs Biotechnology peers
Revenue (TTM)
169.90MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.4970USDUpdated Oct 28, 2026Quarterly Revenue Growth
555.60%vs Biotechnology peers
Gross Profit (TTM)
149.81MUSDvs all stocks (USD)
EBITDA (TTM)
-135.48MUSDvs all stocks (USD)
Net Income (TTM)
-149.83MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
555.64%vs Biotechnology peers
Operating Cash Flow (TTM)
-120.52MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-112.11MUSDvs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00USDUpdated Oct 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Revenue
62.90MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
9.30MUSDFY2025 · Dec 31, 2025Gross Profit
53.60MUSDFY2025 · Dec 31, 2025Operating Income
-213.06MUSDvs all stocks (USD)
Pre-tax Income
-204.63MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-204.63MUSDFY2025 · Dec 31, 2025EBIT
-190.94MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-188.37MUSDFY2025 · Dec 31, 2025Research & Development
115.11MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
151.56MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
21.43MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
13.68MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-204.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-175.98MUSDFY2025 · Dec 31, 2025Free Cash Flow
-176.34MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.74M of depreciation against 354K of capital expenditure, and its own free-cash-flow line reads -181.78M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
164.09MUSDFY2025 · Dec 31, 2025Income Tax Paid
197.00KUSDFY2025 · Dec 31, 2025Interest Paid
2.88MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-204.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.74MUSDFY2025 · Dec 31, 2025Stock-based Compensation
35.89MUSDFY2025 · Dec 31, 2025Other Non-cash Items
11.07MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-3.07MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.13MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.13MUSDFY2025 · Dec 31, 2025Capital Expenditures
-354.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-8.00MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-354.42MUSDFY2025 · Dec 31, 2025Sale of Investments
462.29MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
107.52MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-11.90MUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
48.20MUSDFY2025 · Dec 31, 2025Other Financing Charges
142.91MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
179.22MUSDFY2025 · Dec 31, 2025Shares Outstanding
349.82MSharesUpdated Oct 28, 2026Float Shares
263.65MSharesUpdated Oct 28, 2026Shares Short
58.86MSharesUpdated Oct 28, 2026Short Ratio
12.54daysvs all stocks
Short % of Shares Outstanding
27.61%vs all stocks
% Held by Insiders
17.19%vs all stocks
% Held by Institutions
67.83%vs all stocks
Total Cash (MRQ)
660.96MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.88USDUpdated Oct 28, 2026Total Debt (MRQ)
416.26MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.64xvs Biotechnology peers
Current Ratio (MRQ)
8.37xvs Biotechnology peers
Book Value per Share (MRQ)
0.7260USDUpdated Oct 28, 2026Total Assets
594.82MUSDvs all stocks (USD)
Total Current Assets
571.52MUSDFY2025 · Dec 31, 2025Total Liabilities
289.11MUSDFY2025 · Dec 31, 2025Total Non-current Assets
23.30MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
206.88MUSDFY2025 · Dec 31, 2025Total Current Liabilities
82.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
164.09MUSDFY2025 · Dec 31, 2025Other Short-term Investments
365.13MUSDFY2025 · Dec 31, 2025Accounts Receivable
16.08MUSDFY2025 · Dec 31, 2025Inventory
11.41MUSDFY2025 · Dec 31, 2025Accounts Payable
9.48MUSDFY2025 · Dec 31, 2025Short-term Debt
7.60MUSDFY2025 · Dec 31, 2025Deferred Revenue
7.51MUSDFY2025 · Dec 31, 2025Other Current Liabilities
12.45MUSDFY2025 · Dec 31, 2025Long-term Debt
49.75MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
145.82MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.42BUSDFY2025 · Dec 31, 2025Retained Earnings
-1.12BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
305.72MUSDvs all stocks (USD)
52-Week Low
3.92USDUpdated Oct 28, 202652-Week High
9.75USDUpdated Oct 28, 202652-Week Change
-13.50%vs all stocks
Beta
1.62xvs all stocks
50-Day MA
5.81USDUpdated Oct 28, 2026200-Day MA
5.44USDUpdated Oct 28, 2026Avg 10-Day Volume
4.89MSharesUpdated Oct 28, 2026Avg 30-Day Volume
5.28MSharesUpdated Oct 28, 2026Diluted EPS (TTM)
-0.4400USDUpdated Oct 28, 2026Other Income / Expense
689.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: -0.88
Significant cash reserves alongside high leverageNotable
Cash (USD): 660,956,032Total Debt (USD): 416,263,008Debt-to-Equity: 1.64
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 8.37Altman Z-Score: 0.72
Financial Health
Altman Z-Score 0.72: distress zoneCritical
Altman Z-Score: 0.72
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.6B, above the global median of $1.14BNotable
Market cap (USD): 1,597,610,710Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alembic Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Consun Pharmaceutical Group Limited
Tier 1ProductionApproval-Gated PipelineRule
Qingdao Haier Biomedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai MicroPort Endovascular MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
MeHow Innovative Ltd.
Tier 1ProductionApproval-Gated PipelineRule